-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tumors rank second in the U.S. in disease mortality, according to the study, and the American Cancer Society predicts that the number of new lung cancer cases alone will reach 235,000 in 2018, while the number of deaths will be 155,000.
, advanced non-small cell lung cancer is the most common pathological type of lung cancer, accounting for about 80% to 85%.
the incidence of ROS1 gene rearming/fusion in non-small cell lung cancer (non-small cell lung cancer, NSCLC) is about 1% to 2%, and about 2,000 to 4,500 new ROS1 fusion gene-positive NSCLC patients are added in the United States each year.
Point Therapeutics, a precision oncology company, recently announced that the ongoing REVIEW-1 registration study for the treatment of ROS1-positive non-small cell lung cancer has yielded interim results.
of 15 patients recruited in phase 2 of the TRIDENT-1 study, preliminary efficacy analysis showed that the objective remission rate (ORR) was 93% (95% CI:68-100) assessed by doctors.
Mohammad Hirmand, chief medical officer of Turing Point Therapeutics, said: "These interim data confirm our belief that repotrectinib has the potential to be the best treatment for patients with ros1-positive advanced non-small cell lung cancer."
